Human Drug Off-label Veterinary Use in U.S., By Application (Sedatives/Analgesics and Oncology)

Deliverable Overview

The animal health team at Grand View Research has developed a comprehensive trend report on the off-label use of human-approved drugs in the U.S. veterinary sector. This report provides both qualitative and quantitative insights, including key market drivers, restraints, challenges, opportunities, business activities, and regulatory landscape. It focuses on two primary therapeutic areas: sedatives/analgesics and oncology. Sedatives/analgesics analysed include Buprenorphine, Diazepam, Propofol, Butorphanol, Dexmedetomidine, Fentanyl, Hydromorphone, and Methadone, while oncology drugs include Carboplatin, Doxorubicin, Vinblastine, Vincristine, Chlorambucil, Cyclophosphamide, and Lomustine. Additionally, the report offers SKU-level market value & volume data for the most prescribed drugs by veterinarians in the U.S.

Report Overview

The off-label use of human-approved drugs in the U.S. veterinary sector is a widespread and essential practice, particularly when suitable veterinary-labelled alternatives are unavailable or insufficient. Permitted under the FDA's Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994, this provision allows licensed veterinarians to prescribe human animal medications under carefully regulated conditions. Off-label prescribing plays a vital role in pain management, sedation, anesthesia, and cancer treatment in companion animals. For example, human-approved sedatives and analgesics like buprenorphine, diazepam, and fentanyl are commonly used in veterinary care to manage acute and chronic pain.

In oncology, off-label use is even more prominent due to the limited availability of veterinary-specific chemotherapeutics. Drugs such as carboplatin, vincristine, and doxorubicin are used to treat a variety of cancers in pets, often forming the backbone of veterinary chemotherapy protocols. When carefully dosed and monitored, these medications help extend survival and improve the quality of life for animal patients. Despite challenges in dosing, safety, and regulation, off-label drug use remains a cornerstone of advanced veterinary practice.

The final deliverable will be presented in the following format.: 

                                 Human Oncology Drug Off-label Veterinary Use in U.S. 

                           Human Sedatives/Analgesics Drug Off-label Veterinary Use in U.S. 

The regulatory landscape for off-label use of human drugs in veterinary medicine is shaped by several key bodies, including the FDA's Center for Veterinary Medicine (CVM), the DEA, and state veterinary boards. The FDA allows off-label drug use under the Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994, permitting veterinarians to prescribe human drugs for animals based on medical judgment. However, such use requires careful consideration of safety, efficacy, and appropriate dosages, as human medications may have different effects in animals.

Controlled substances like fentanyl, hydromorphone, and methadone are subject to strict DEA regulations. Commonly used off-label drugs in veterinary medicine include sedatives/analgesics (buprenorphine, diazepam, propofol) and oncology drugs (carboplatin, doxorubicin, vincristine), many of which are approved for human use but lack formal approval for specific animal species. Despite the risks, off-label use is essential due to the limited availability of FDA-approved veterinary drugs. However, veterinarians must ensure adherence to legal guidelines and carefully monitor the animals for adverse effects.

Human Drug Off-label Veterinary Use in U.S., Report Scope

The first section of the deliverable consists of around 15 leading drugs across various applications, such as sedation/analgesia and oncology, used off-label for veterinary purposes in the U.S. Furthermore, the second section of this report will include an assessment of the latest market dynamics, regulatory landscape, and other business activities shaping this market's trend.